The impact of PRMT1 on the upregulation of ME2 expression was examined following the addition of MG132, a proteasome inhibitor, and chloroquine, a lysosomal inhibitor, to the cells to better elucidate the mechanism by which PRMT1 controls ME2 in HCC, and Western blotting showed that chloroquine and MG132 reversed the decrease in ME2 levels induced by PRMT1 knockdown (Fig. 6A). The gene discussed is PRMT1; the disease is hepatocellular carcinoma.